Endocannabinoids in the treatment of gastrointestinal inflammation and symptoms. (December 2018)
- Record Type:
- Journal Article
- Title:
- Endocannabinoids in the treatment of gastrointestinal inflammation and symptoms. (December 2018)
- Main Title:
- Endocannabinoids in the treatment of gastrointestinal inflammation and symptoms
- Authors:
- Pesce, Marcella
Esposito, Giuseppe
Sarnelli, Giovanni - Abstract:
- Highlights: The use of Cannabis as a complementary and alternative medicine in inflammatory bowel disease has increased due to the evolving policies regarding its legalization. Endocannabinoids in IBD represent both an appealing therapeutic strategy and a captivating scientific dilemma. Results from clinical trials must be carefully interpreted owing to possible reporting-biases related to cannabinoids psychotropic effects. Also, discriminating between symptomatic improvement and the real gain on the underlying inflammatory process is often challenging. Despite these limitations in the current use of these drugs in clinical practice, several novel therapeutic strategies are under consideration to overcome these flaws. Abstract : The evolving policies regarding the use of therapeutic Cannabis have steadily increased the public interest in its use as a complementary and alternative medicine in several disorders, including inflammatory bowel disease. Endocannabinoids represent both an appealing therapeutic strategy and a captivating scientific dilemma. Results from clinical trials have to be carefully interpreted owing to possible reporting-biases related to cannabinoids psychotropic effects. Moreover, discriminating between symptomatic improvement and the real gain on the underlying inflammatory process is often challenging. This review summarizes the advances and latest discovery in this ever-changing field of investigation, highlighting the main limitations in the currentHighlights: The use of Cannabis as a complementary and alternative medicine in inflammatory bowel disease has increased due to the evolving policies regarding its legalization. Endocannabinoids in IBD represent both an appealing therapeutic strategy and a captivating scientific dilemma. Results from clinical trials must be carefully interpreted owing to possible reporting-biases related to cannabinoids psychotropic effects. Also, discriminating between symptomatic improvement and the real gain on the underlying inflammatory process is often challenging. Despite these limitations in the current use of these drugs in clinical practice, several novel therapeutic strategies are under consideration to overcome these flaws. Abstract : The evolving policies regarding the use of therapeutic Cannabis have steadily increased the public interest in its use as a complementary and alternative medicine in several disorders, including inflammatory bowel disease. Endocannabinoids represent both an appealing therapeutic strategy and a captivating scientific dilemma. Results from clinical trials have to be carefully interpreted owing to possible reporting-biases related to cannabinoids psychotropic effects. Moreover, discriminating between symptomatic improvement and the real gain on the underlying inflammatory process is often challenging. This review summarizes the advances and latest discovery in this ever-changing field of investigation, highlighting the main limitations in the current use of these drugs in clinical practice and the possible future perspectives to overcome these flaws. … (more)
- Is Part Of:
- Current opinion in pharmacology. Volume 43(2018)
- Journal:
- Current opinion in pharmacology
- Issue:
- Volume 43(2018)
- Issue Display:
- Volume 43, Issue 2018 (2018)
- Year:
- 2018
- Volume:
- 43
- Issue:
- 2018
- Issue Sort Value:
- 2018-0043-2018-0000
- Page Start:
- 81
- Page End:
- 86
- Publication Date:
- 2018-12
- Subjects:
- Pharmacology -- Periodicals
Pharmaceutical Preparations -- Periodicals
Drug Therapy -- Periodicals
Biopharmaceutics -- Periodicals
Pharmacologie -- Périodiques
Pharmacology
Periodicals
615.105 - Journal URLs:
- http://www.sciencedirect.com/science/journal/14714892 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/14714892 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/14714892 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.coph.2018.08.009 ↗
- Languages:
- English
- ISSNs:
- 1471-4892
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3500.776920
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 11390.xml